LEI: 213800H188ZDCWWXFA21
Creo Medical Group plc
("Creo" or the "Company")
Director/PDMR Share Dealings
The Company has been informed that on 30 May 2025, Kevin T. Crofton, Non-Executive Chairman, purchased Ordinary Shares in the Company at an average price of 15.75 pence per share as follows:
| Director/PDMR Name | No. of Ordinary Shares Acquired | Resultant Shareholding post transaction | % of voting rights post transaction |
| Kevin T. Crofton | 701,750 | 5,447,416 | 1.32% |
This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation, and contains inside information.
Notification and public disclosure of transactions by persons discharging managerial responsibilities.
For further information please contact:
| Creo Medical Group plc | ||
| Richard Craven, Company Secretary | Via Walbrook PR | |
| | | |
| Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Sher Shah | +44 (0)20 7260 1000 | |
|
| | |
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com | |
| Paul McManus / Alice Woodings
| Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Kevin T. Crofton
| |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Chairman
| |
| b) | Initial notification/Amendment | Initial Notification
| |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Creo Medical Group plc
| |
| b) | LEI | 213800H188ZDCWWXFA21
| |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each
| |
| | Identification code | GB00BZ1BLL44
| |
| b) | Nature of the transaction | Purchase of Ordinary Shares
| |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.1575 per share
| 701,750 | ||
| d) | Aggregated information
| | |
| | Aggregated volume | 701,750 | |
| | Price | £110,525.63
| |
| e) | Date of the transaction | 30 May 2025
| |
| f) | Place of the transaction | London Stock Exchange
| |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.